Alessandro Maselli has served as President and Chief Executive Officer of Catalent since July 2022. Previously, he was the company’s President & Chief Operating Officer, a role he held since February 2019.

Mr. Maselli joined Catalent in 2010 as Director of Operations at the company’s pharmaceutical, nutritional, and cosmetics facility in Aprilia, Italy. Since then, he has held roles of increasing responsibility, assuming the role of General Manager of Zydis® operations at Catalent’s Swindon, UK facility in 2013; Vice President of Operations, Europe, for the Drug Delivery Solutions business in 2015; and Senior Vice President, Global Operations in 2016.

Before joining Catalent, Mr. Maselli held operational and business leadership roles at Alstom, SGS, and ABB. He began his career as an automation systems engineer in the food industry.

Mr. Maselli currently serves on the Board of Directors of Graphic Packaging Holding Company.

A native of Italy, Mr. Maselli holds a master’s degree in engineering from the University of Rome.

Lisa Evoli was named Senior Vice President and Chief Human Resources Officer in August 2023. In this role, she leads Catalent’s global human resources strategy, including talent acquisition, leadership development, diversity and inclusion, organizational design, compensation and benefits, HR operations and technology, and performance management. Prior to joining Catalent, Lisa spent over 25 years in various senior HR leadership roles at Integra Lifesciences, TE Connectivity, Johnson & Johnson, and Motorola. Lisa holds a bachelor’s degree in business administration from the California University of Pennsylvania and a master’s degree in human resources development from Villanova University.

Joseph A. Ferraro serves as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary of Catalent. He joined the company in February 2023 and is responsible for overseeing Catalent’s global legal, compliance, and corporate governance functions.

Mr. Ferraro brings over two decades of legal and regulatory experience across complex public companies and private equity-backed enterprises. Prior to joining Catalent, he was Chief Legal Officer and Secretary at Innovate Corp., a public holding company, where he led global legal and compliance operations across a broad portfolio of businesses. Before that, he served as General Counsel and Deputy Chief Compliance Officer at Prospect Capital Corporation, a publicly traded business development company.

Earlier in his career, Mr. Ferraro practiced corporate and securities law at Sullivan & Cromwell LLP and Boies Schiller Flexner LLP, advising clients on complex transactions, governance, and regulatory matters.

Mr. Ferraro holds a Juris Doctor degree with honors from The Law School at the University of Chicago, where he served as a Managing Editor of the University of Chicago Law Review, and a Bachelor of Arts cum laude in Public and International Affairs from Princeton University. He actively serves as Board Chair at Far Hills Country Day School, President of the Delbarton School Alumni Association, and sits on the Board of Trustees of Delbarton School.

Aris Gennadios was named Group President, Pharma and Consumer Health in July 2022. Prior to that, he served as President of our Softgel & Oral Technologies business since September 2013 and, earlier, as Vice President and General Manager of Softgel Technologies. Dr. Gennadios has worked in the pharmaceutical industry since 1996 in roles including R&D, field sales, business development, operations, and leadership.

He joined Catalent’s predecessor company, Cardinal Health, in 2002 and held several leadership posts within the softgel technologies business, including Global Vice President of Business Development for Softgel Technologies, General Manager of the Oral Development Center in Somerset, NJ, and Vice President and General Manager for Rx Softgel and Consumer Health products.

Dr. Gennadios earned his bachelor’s degree in chemical engineering from the National Technical University of Athens, Greece and his master’s degree in agricultural engineering from Clemson University. Dr. Gennadios holds a doctorate in engineering from the University of Nebraska and an MBA from Wake Forest University.

Scott Gunther was named Senior Vice President of Quality & Regulatory Affairs in May 2017. Mr. Gunther joined Catalent in 2012 as Vice President, Quality and most recently has been overseeing the quality function for the United States sites in our Drug Delivery Solutions business unit. He previously also concurrently served as an interim Vice President of Product Development for the DDS business unit.

Prior to joining Catalent, Scott spent 22 years with Bristol-Myers-Squibb in various roles of increasing responsibility. In his last role at BMS, he held the position of Executive Director Quality Operations Americas, where he was responsible for quality operations at its manufacturing sites in the U.S., Puerto Rico, and Latin America.

Scott holds a Bachelor of Science degree from the State University of New York at Buffalo and an MBA from Canisius College.

Tom Hawkeswood was appointed Senior Vice President, Global Operations and joined the Group Executive Committee in September 2025. In this role, Tom leads Catalent’s global operations, drawing on more than 25 years of leadership experience across multiple industries and contract manufacturing environments.

Tom has held a series of increasingly senior roles since joining Catalent in 2017 as Vice President and General Manager of the company’s Canadian softgel sites, following the acquisition of Accucaps Industries Limited. Most recently, he served as Group Vice President & General Manager of Pharma and Consumer Health Operations, and previously as President and Division Head of Pharma Product Delivery. Earlier, he was Vice President, Operations for the former Softgel & Oral Technologies business, overseeing regions of expanding scope and complexity.

Tom began his career with six years at a subsidiary of ThyssenKrupp and spent a decade at Accucaps Industries Limited in roles of increasing responsibility. He holds a bachelor’s degree in mechanical engineering from Queen’s University and an MBA from the University of Windsor, both in Ontario, Canada.

Ricky Hopson was named Group President, Clinical and Specialty Services in addition to his Chief of Staff role in January of 2025. He served as President, Division Head for BioProduct Delivery and Chief of Staff from August 2023 to January 2025. During his 23 years with Catalent, Mr. Hopson has held a variety of leadership and finance roles, including President, Division Head for Clinical & Development Services, Interim Chief Financial Officer, Chief Accounting Officer, Global Vice President of Operational Finance, and Vice President of Finance for two different business units.

Mr. Hopson graduated from the University of Portsmouth and is a chartered management accountant in the U.K.

Charles Lickfold was named Senior Vice President and Chief Technology Officer in December 2024. Mr. Lickfold joined Catalent in 2020 as Senior Vice President and Chief Information Officer. Prior to joining Catalent, he held numerous IT leadership positions, including CIO for Alcami Corp., Avara Pharmaceutical Services, and Gilbarco-Veeder-Root. He also served as Vice President and Head of IT for Patheon and began his career as a management consultant in the life sciences practice of Ernst & Young LLP. He earned a bachelor’s degree in computer science from the University of Kentucky’s College of Engineering.

Matti Masanovich joined Catalent as Senior Vice President & Chief Financial Officer in July 2023 as a member of Catalent’s executive leadership team. His responsibilities include all aspects of Catalent’s global financial operations, including financial planning and analysis, controllership, public reporting and investor relations, capital markets activities, bill payment and collection, tax, and treasury.

Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was acquired by Apollo. Previously he was Chief Financial Officer at Superior Industries International and General Cable Corporation.

Earlier in his career, Mr. Masanovich held finance leadership roles of increasing responsibility in a number of companies in the automotive industry, where he demonstrated a strong history of improvement and profitability and operating efficiency. Mr. Masanovich began his career with PricewaterhouseCoopers LLP. He has Bachelor of Commerce, Finance & Accounting and M.B.A. degrees from the University of Windsor and is a Chartered Accountant in Canada.

David McErlane joined Catalent as Group President of Biologics in September 2023 as a member of Catalent’s executive leadership team. In this role, he leads all of Catalent’s Biologics businesses and global service offerings – including development, drug substance manufacturing, drug product fill-and-finish, cell and gene therapy, and analytical services.

Prior to joining Catalent, Mr. McErlane served as senior vice president and business unit head for Lonza’s Bioscience business – where he led strategy, sales, marketing, innovation, digital, and operations functions for this division while developing transformational business strategies, executing major investments to digitize the customer journey, and acquiring and integrating new technologies.

Earlier in his career, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca. He holds a bachelor’s degree in electronic systems engineering from Glasgow Caledonian University.

John Greisch has been a member of the Catalent Board since February 2018, including serving as Executive Chair from August 2023 to December 2024. He served as President and Chief Executive Officer of Hill-Rom Holdings, Inc. from 2010 until his retirement in 2018. Prior to Hill-Rom, Mr. Greisch was President, International Operations for Baxter International, Inc. from 2006 to 2009. While at Baxter, he also served as Chief Financial Officer from 2004 to 2006 and as President of its bioscience division from 2003 to 2004. Previously, Mr. Greisch was President and Chief Executive Officer for FleetPride Corporation from 1998 to 2001. Prior to that, he held various positions at The Interlake Corporation from 1986 to 1997.

Mr. Greisch is Lead Independent Director of Carrier’s Board of Directors, and Chairman of the Board of Discovery Life Sciences and Viant Medical. He previously served as a director of Cerner Corporation from 2019 to 2022, Idorsia Pharmaceuticals Ltd. from 2017 to 2020, Hill-Rom from 2010 to 2018, and Actelion Ltd., from 2013 to 2017. He is on the Board of Directors for the Ann & Robert H. Lurie Children’s Hospital of Chicago. Mr. Greisch holds a bachelor’s degree from Miami University (Ohio) and an MBA from the Kellogg School of Management at Northwestern University.

Jon Levy joined Novo Principal Investments in September 2020 as a Senior Partner, to further the team’s presence in the United States.

He brings over 10 years of healthcare private equity experience as well as several years as an investment banker. Most recently, Mr. Levy served as a Managing Director in the healthcare team at CVC Capital Partners based in New York. Prior to joining CVC, he worked at private equity firms LetterOne Health and Tailwind Capital Partners as well as the investment bank Lazard.

Mr. Levy has a BA in Ethics, Politics and Economics from Yale University and an MBA from Columbia Business School.

Sue Mahony is a senior executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served in a variety of senior leadership positions at Eli Lilly and Company from 2000 to 2018, most recently as Senior Vice President and President of Lilly Oncology and a member of the executive committee of Eli Lilly. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen and Bristol Myers Squibb. She currently serves on the board of directors of Assembly Biosciences, Inc., Axsome Therapeutics, Inc. and Zymeworks, Inc., and she previously served on the board of directors of Horizon Therapeutics, plc and Vifor Pharma.

Dr. Mahony received a BSc and a PhD from Aston University and an MBA from London Business School.

Alessandro Maselli has served as President and Chief Executive Officer of Catalent since July 2022. Previously, he was the company’s President & Chief Operating Officer, a role he held since February 2019.

Mr. Maselli joined Catalent in 2010 as Director of Operations at the company’s pharmaceutical, nutritional, and cosmetics facility in Aprilia, Italy. Since then, he has held roles of increasing responsibility, assuming the role of General Manager of Zydis® operations at Catalent’s Swindon, UK facility in 2013; Vice President of Operations, Europe, for the Drug Delivery Solutions business in 2015; and Senior Vice President, Global Operations in 2016.

Before joining Catalent, Mr. Maselli held operational and business leadership roles at Alstom, SGS, and ABB. He began his career as an automation systems engineer in the food industry.

Mr. Maselli currently serves on the Board of Directors of Graphic Packaging Holding Company.

A native of Italy, Mr. Maselli holds a master’s degree in engineering from the University of Rome.

Charles Patten is a Partner with Novo Holdings, which he joined in June 2021. He participates in deal sourcing and execution as well as in managing and developing a growing portfolio of investments.

Prior to joining Novo Holdings, Mr. Patten worked at Anchorage Capital Group, CVC Capital Partners, and Morgan Stanley. He holds a BSc in Economics from the Wharton School of the University of Pennsylvania.

Marie-France Tschudin is a global healthcare leader with 30 years of experience in the biotechnology and pharmaceutical industry. Until September 2023, Ms. Tschudin was President, Innovative Medicines International & Chief Commercial Officer of Novartis Pharma AG and a member of the Executive Committee. Before that, she held increasingly senior leadership positions, including President, Novartis Pharmaceuticals. Prior to joining Novartis, Ms. Tschudin spent 10 years at Celgene International in a variety of leadership positions across Europe. Ms. Tschudin started her career as a sales representative and then held a number of sales and marketing positions at Johnson & Johnson and Schering-Plough.

Currently, she is a Board Director for AXA Group and Mars, Inc. Ms. Tschudin graduated with an MBA from IMD business school in Switzerland, and a Bachelor of Science from Georgetown University.

Tim Walbert served as the Chairman, President and Chief Executive Officer of Horizon Therapeutics from 2008 to October 2023, when it was acquired by Amgen for $28.3 billion. Before joining Horizon, he held various executive leadership positions across biotech and pharma companies, including  at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA. Mr. Walbert serves on the boards of directors of Biomarin, Century Therapeutics and Sagimet Biosciences, all public biotech companies and Cour Pharmaceuticals, Odyssey Therapeutics and Latigo Therapeutics (chairman), all private clinical-stage biotech companies. Mr. Walbert received a Bachelor of Arts in Business from Muhlenberg College in Allentown, PA and now serves as a member of the College’s Board of Trustees.